Estados Unidos - inglés - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - zaleplon (unii: s62u433rmh) (zaleplon - unii:s62u433rmh) - zaleplon 5 mg - zaleplon is indicated for the short-term treatment of insomnia. zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see clinical trials   under clinical pharmacology ). it has not been shown to increase total sleep time or decrease the number of awakenings. the clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. the final formal assessments of sleep latency were performed at the end of treatment. hypersensitivity to zaleplon or any excipients in the formulation (see also precautions). zaleplon is classified as a schedule iv controlled substance by federal regulation. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaption that is manifested by a specific withdrawal syndrome that can be produced by abrupt ces

Estados Unidos - inglés - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - zaleplon (unii: s62u433rmh) (zaleplon - unii:s62u433rmh) - zaleplon 10 mg - zaleplon is indicated for the short-term treatment of insomnia. zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see clinical trials   under clinical pharmacology ). it has not been shown to increase total sleep time or decrease the number of awakenings. the clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. the final formal assessments of sleep latency were performed at the end of treatment. hypersensitivity to zaleplon or any excipients in the formulation (see also precautions). zaleplon is classified as a schedule iv controlled substance by federal regulation. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaption that is manifested by a specific withdrawal syndrome that can be produced by abrupt ces

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

welland medical ltd -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

welland medical ltd -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

welland medical ltd -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

pelican healthcare ltd -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

pelican healthcare ltd -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

salts healthcare -

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - bifenthrin; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - bifenthrin pyrethroid active 100.0 g/l; n-methyl-2-pyrrolidone solvent other 50.0 g/l; liquid hydrocarbon solvent other 605.0 g/l - insecticide

Israel - inglés - Ministry of Health

astrazeneca (israel) ltd - aclidinium bromide - powder for inhalation - aclidinium bromide 0.4 mg - aclidinium bromide - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)